


2008), Krüppel-like factor 15 (KLF15; Takashima et al., 2010), and cyclic AMP (cAMP) response element binding protein (CREB; Rozance et al., 2008). While we were analyzing these factors in both HCV replicon cells and HCV J6/JFH1-infected cells, we found the involvement of the FoxO1 in the transcriptional activation of G6Pase and PEPCK (Deng et al., 2011). It is known that the FoxO1 enhances gluconeogenesis through the transcriptional activation of various genes, including G6Pase and PEPCK (Gross et al., 2008). The function of FoxO1 is regulated by post-translational modifications, including phosphorylation, ubiquitylation, and acetylation (Tzivion et al., 2011). The phosphorylated form of FoxO1 is exported from the nucleus to the cytosol, resulting in loss of its transcriptional activity (Figure 2). Phosphorylation status of FoxO1 at Ser319 is critical for FoxO1 nuclear exclusion (Zhao et al., 2004). Although the total amounts of FoxO1 protein were unchanged, FoxO1 phosphorylation at Ser319 was markedly suppressed in HCV-infected cells compared to that in the mock-infected cells. It is known that the FoxO1 is phosphorylated by the protein kinase Akt and is exported from the nucleus to the cytosol, resulting in loss of its transcriptional activity (Tzivion et al., 2011). The majority of FoxO1 was accumulated in the nuclear fraction in HCV-infected cells, whereas in control cells FoxO1 was distributed in both the nuclear and cytoplasmic fractions. Akt phosphorylation was enhanced in HCV-infected cells, although the protein levels of total Akt protein were comparable, which is consistent with the report by Burdette et al. (2010). Our findings suggest an interesting scenario in which the HCV-mediated suppression in FoxO1 phosphorylation is caused by an unknown mechanism independent of Akt activity.

HCV-INDUCED JNK ACTIVATION IS INVOLVED IN THE SUPPRESSION OF FoxO1 PHOSPHORYLATION

It is known that the stress-sensitive serine/threonine kinase JNK regulates FoxO at multiple levels (van der Horst and Burgering, 2007; Karpac and Jasper, 2009). We demonstrated that HCV infection induces phosphorylation and activation of JNK in a time-dependent manner, which is similar to that observed for the suppression of FoxO1 phosphorylation. As a result, c-Jun, a key substrate for JNK, got phosphorylated and activated in HCV-infected cells. The JNK inhibitor SP600125 clearly prevented the phosphorylation of c-Jun, and concomitantly recovered the suppression of FoxO1 phosphorylation in HCV-infected cells, suggesting that HCV activates the JNK/c-Jun signaling pathway, resulting in the nuclear accumulation of FoxO1 by reducing its phosphorylation status. The detailed mechanisms of HCV-induced suppression of FoxO1 phosphorylation via the JNK/c-Jun signaling pathway remain to be explored. There are at least two possibilities. The JNK/c-Jun signaling pathway (1) suppresses a protein kinase, or (2) activates a protein phosphatase to reduce phosphorylation of FoxO1.

HCV-INDUCED MITOCHONDRIAL REACTIVE OXYGEN SPECIES PRODUCTION IS INVOLVED IN INCREASED GLUCOSE PRODUCTION THROUGH JNK ACTIVATION

Hepatitis C virus infection increases mitochondrial reactive oxygen species (ROS) production (Deng et al., 2008). *N*-acetyl cysteine (NAC; a general antioxidant) clearly prevented the phosphorylation of JNK, and concomitantly canceled the suppression of FoxO1 phosphorylation in HCV-infected cells, suggesting that



HCV-induced ROS production is involved in the JNK activation. There was no significant difference in HCV RNA replication or infectious virus release between SP600125- or NAC-treated HCV-infected cells and non-treated HCV-infected cells. These results suggest that ROS-mediated JNK activation plays a key role in the suppression of FoxO1 phosphorylation, nuclear accumulation of FoxO1, and enhancement of glucose production in HCV-infected cells (Deng et al., 2011).

HCV NS5A IS INVOLVED IN THE ENHANCEMENT OF GLUCOSE PRODUCTION

Then we sought to determine which HCV protein(s) is involved in the enhancement of glucose production. Transient expression of NS5A protein in Huh-7.5 cells significantly promoted the gene expression levels of G6Pase and PEPCK determined by real time quantitative RT-PCR. Promoter assay revealed that the level of PEPCK promoter activity was significantly higher in NS5A-expressing cells than in the control cells. Our results suggest that NS5A activate both the PEPCK promoter and the G6Pase promoter, leading to an increase in glucose production (Deng et al., 2011). The study by Banerjee et al. (2010) suggests that the HCV core protein modulates FoxO1 and FoxA2 activation and affects insulin-induced metabolic gene regulation in human hepatocytes. Our results, however, suggest that the HCV core protein is not significantly involved in the increased gluconeogenesis (Deng et al., 2011). The difference between these two studies needs to be explored.

There were previous reports suggesting that ROS production is induced in NS5A-expressing cells (Dionisio et al., 2009) or in hepatocytes of NS5A transgenic mice (Wang et al., 2009). We therefore sought to determine whether NS5A contributes to increased hepatic gluconeogenesis through the induction of ROS production. NS5A-expressing cells displayed a much stronger signal of ROS than in control cells. NS5A-expressing cells promoted phosphorylation level at Ser63 of c-Jun and suppressed FoxO1 phosphorylation at Ser319, suggesting that NS5A mediates JNK/c-Jun activation and FoxO1 phosphorylation suppression. These results suggest that NS5A play a role in the HCV-induced enhancement of hepatic gluconeogenesis through JNK/c-Jun activation and FoxO1 phosphorylation suppression.

CONCLUSION AND FUTURE PERSPECTIVES

Taken together, we propose a model of HCV-induced glucose metabolic disorders as shown in **Figure 2**. HCV infection down-regulates cell surface expression of GLUT2 in hepatocytes at the transcriptional level. HCV down-regulates a transcription factor involved in GLUT2 gene expression through an unknown mechanism. As GLUT2 is a facilitative GLUT, it ensures large bidirectional fluxes of glucose in and out the cell due to its low affinity and high capacity (Leturque et al., 2009). Down-regulated

cell surface expression of GLUT2 results in disruption of bidirectional transport of glucose in hepatocytes. Even in the fasting state, down-regulation of GLUT2 may result in low glucose uptake of hepatocytes, causing hyperglycemia. In the fed state, glucose secretion from hepatocytes may be suppressed due to low level cell surface expression of GLUT2, as GLUT2 is a bidirectional transporter.

Hepatitis C virus infection induces mitochondria damage and ROS production, leading to JNK activation. HCV NS4A protein is involved in mitochondrial damage (Nomura-Takigawa et al., 2006). HCV NS5A protein is involved in ROS production (Dionisio et al., 2009; Wang et al., 2009; Deng et al., 2011). HCV-induced ROS production causes JNK activation, which results in the decreased phosphorylation and nuclear accumulation of FoxO1 by an unidentified mechanism. Nuclear accumulation of FoxO1 up-regulates gene expression of PEPCK and G6Pase, leading eventually to increased glucose production by gluconeogenesis (Deng et al., 2011).

These two pathways, HCV-induced down-regulation of GLUT2 expression and up-regulation of gluconeogenesis, may contribute to development of type 2 diabetes in HCV-infected patients at least to some extent. HCV-induced down-regulation of GLUT2 expression and up-regulation of gluconeogenesis may result in high concentration of glucose in HCV-infected hepatocytes. As suggested in a recent study, low glucose concentration in the hepatocytes inhibits HCV replication (Nakashima et al., 2011). Therefore, high glucose levels in the hepatocytes may confer an advantage in efficient replication of HCV.

Our understanding of HCV-induced glucose metabolic disorders will require much more work to fully unfold this pathway. Further investigation including the mechanism of HCV-induced GLUT2 downregulation, JNK-mediated decreased phosphorylation of FoxO1, and the possible effect(s) of the dysregulation of hepatic gluconeogenesis on the HCV life cycle and host cells are currently under way.

ACKNOWLEDGMENTS

The authors are grateful to all of their co-workers who contributed to the studies cited here. This work was supported in part by grants-in-aid for Research on Hepatitis from the Ministry of Health, Labor and Welfare, Japan, and the Japan Initiative for Global Research Network on Infectious Diseases (J-GRID) program of Ministry of Education, Culture, Sports, Science and Technology, Japan. This study was also carried out as part of the Global Center of Excellence program of Kobe University Graduate School of Medicine, and the Science and Technology Research Partnership for Sustainable Development (SATREPS) program of Japan Science and Technology Agency (JST) and Japan International Cooperation Agency (JICA).

REFERENCES

- Banerjee, A., Meyer, K., Mazumdar, B., Ray, R. B., and Ray, R. (2010). Hepatitis C virus differentially modulates activation of forkhead transcription factors and insulin-induced metabolic gene expression. *J. Virol.* 84, 5936–5946.
- Bunyoku, Y., Shoji, I., Makine, T., Adachi, T., Hayashida, K., Nagano-Fujii, M., Ide, Y. H., Deng, L., and Hotta, H. (2009). Efficient production of infectious hepatitis C virus with adaptive mutations in cultured hepatoma cells. *J. Gen. Virol.* 90, 1681–1691.
- Burdette, D., Olivarez, M., and Waris, G. (2010). Activation of transcription factor Nrf2 by hepatitis C virus induces the cell-survival pathway. *J. Gen. Virol.* 91, 681–690.
- Choo, Q. L., Richman, K. H., Han, J. H., Berger, K., Lee, C., Dong, C., Gallegos, C., Coit, D., Medina-Selby,

- R., Barr, P. J., Weiner, A. J., Bredley, D. W., Kuo, G., and Houghton, M. (1991). Genetic organization and diversity of the hepatitis C virus. *Proc. Natl. Acad. Sci. U.S.A.* 88, 2451–2455.
- Clore, J. N., Stillman, J., and Sugerman, H. (2000). Glucose-6-phosphatase flux in vitro is increased in type 2 diabetes. *Diabetes* 49, 969–974.
- Deng, L., Adachi, T., Kitayama, K., Bungyoku, Y., Kitazawa, S., Ishido, S., Shoji, I., and Hotta, H. (2008). Hepatitis C virus infection induces apoptosis through a Bax-triggered, mitochondrion-mediated, caspase 3-dependent pathway. *J. Virol.* 82, 10375–10385.
- Deng, L., Shoji, I., Ogawa, W., Kaneda, S., Soga, T., Jiang, D. P., Ide, Y. H., and Hotta, H. (2011). Hepatitis C virus infection promotes hepatic gluconeogenesis through an NS5A-mediated, FoxO1-dependent pathway. *J. Virol.* 85, 8556–8568.
- Dionisio, N., Garcia-Mediavilla, M. V., Sanchez-Campos, S., Majano, P. L., Benedicto, I., Rosado, J. A., Salido, G. M., and Gonzalez-Gallego, J. (2009). Hepatitis C virus NS5A and core proteins induce oxidative stress-mediated calcium signalling alterations in hepatocytes. *J. Hepatol.* 50, 872–882.
- Godoy, A., Ulloa, V., Rodriguez, F., Reinicke, K., Yanez, A. J., Garcia Mde, L., Medina, R. A., Carrasco, M., Barberis, S., Castro, T., Martinez, F., Koch, X., Vera, J. C., Poblete, M. T., Figueroa, C. D., Peruzzo, B., Perez, F., and Nualart, F. (2006). Differential subcellular distribution of glucose transporters GLUT1-6 and GLUT9 in human cancer: ultrastructural localization of GLUT1 and GLUT5 in breast tumor tissues. *J. Cell. Physiol.* 207, 614–627.
- Gross, D. N., van den Heuvel, A. P., and Birnbaum, M. J. (2008). The role of FoxO in the regulation of metabolism. *Oncogene* 27, 2320–2336.
- Hirota, K., Sakamaki, J., Ishida, J., Shimamoto, Y., Nishihara, S., Kodama, N., Ohta, K., Yamamoto, M., Tanimoto, K., and Fukamizu, A. (2008). A combination of HNF-4 and Foxo1 is required for reciprocal transcriptional regulation of glucokinase and glucose-6-phosphatase genes in response to fasting and feeding. *J. Biol. Chem.* 283, 32432–32441.
- Karpac, J., and Jasper, H. (2009). Insulin and JNK: optimizing metabolic homeostasis and lifespan. *Trends Endocrinol. Metab.* 20, 100–106.
- Kasai, D., Adachi, T., Deng, L., Nagano-Fujii, M., Sada, K., Ikeda, M., Kato, N., Ide, Y. H., Shoji, I., and Hotta, H. (2009). HCV replication suppresses cellular glucose uptake through down-regulation of cell surface expression of glucose transporters. *J. Hepatol.* 50, 883–894.
- Kawaguchi, T., Yoshida, T., Harada, M., Hisamoto, T., Nagao, Y., Ide, T., Taniguchi, E., Kumemura, H., Hanada, S., Maeyama, M., Baba, S., Koga, H., Kumashiro, R., Ueno, T., Ogata, H., Yoshimura, A., and Sata, M. (2004). Hepatitis C virus down-regulates insulin receptor substrates 1 and 2 through up-regulation of suppressor of cytokine signaling 3. *Am. J. Pathol.* 165, 1499–1508.
- Koike, K. (2007). Hepatitis C virus contributes to hepatocarcinogenesis by modulating metabolic and intracellular signaling pathways. *J. Gastroenterol. Hepatol.* 22(Suppl. 1), S108–S111.
- Lemon, S. M., Walker, C., Alter, M. J., and Yi, M. (2007). “Hepatitis C virus,” in *Fields’ Virology*, 5th Edn, eds B. N. Fields, D. M. Knipe, and P. M. Howley (Philadelphia, PA: Wolters Kluwer Health/Lippincott Williams and Wilkins), 1291–1304.
- Leturque, A., Brot-Laroche, E., and Le Gall, M. (2009). GLUT2 mutations, translocation, and receptor function in diet sugar managing. *Am. J. Physiol. Endocrinol. Metab.* 296, E985–E992.
- Lindenbach, B. D., Evans, M. J., Syder, A. J., Wolk, B., Tellinghuisen, T. L., Liu, C. C., Maruyama, T., Hynes, R. O., Burton, D. R., McKeating, J. A., and Rice, C. M. (2005). Complete replication of hepatitis C virus in cell culture. *Science* 309, 623–626.
- Lohmann, V., Korner, F., Koch, J., Herian, U., Theilmann, L., and Bartenschlager, R. (1999). Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. *Science* 285, 110–113.
- Macheda, M. L., Rogers, S., and Best, J. D. (2005). Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer. *J. Cell. Physiol.* 202, 654–662.
- Mason, A. L., Lau, J. Y., Hoang, N., Qian, K., Alexander, G. J., Xu, L., Guo, L., Jacob, S., Regenstein, F. G., Zimmerman, R., Everhart, J. E., Wasserfall, C., Maclaren, N. K., and Perillo, R. P. (1999). Association of diabetes mellitus and chronic hepatitis C virus infection. *Hepatology* 29, 328–333.
- Miyamoto, H., Moriishi, K., Moriya, K., Murata, S., Tanaka, K., Suzuki, T., Miyamura, T., Koike, K., and Matsuura, Y. (2007). Involvement of the PA28gamma-dependent pathway in insulin resistance induced by hepatitis C virus core protein. *J. Virol.* 81, 1727–1735.
- Nakashima, K., Takeuchi, K., Chihara, K., Hotta, H., and Sada, K. (2011). Inhibition of hepatitis C virus replication through adenosine monophosphate-activated protein kinase-dependent and -independent pathways. *Microbiol. Immunol.* 55, 774–782.
- Negro, F. (2011). Mechanisms of hepatitis C virus-related insulin resistance. *Clin. Res. Hepatol. Gastroenterol.* 35, 358–363.
- Negro, F., and Alaei, M. (2009). Hepatitis C virus and type 2 diabetes. *World J. Gastroenterol.* 15, 1537–1547.
- Nomura-Takigawa, Y., Nagano-Fujii, M., Deng, L., Kitazawa, S., Ishido, S., Sada, K., and Hotta, H. (2006). Non-structural protein 4A of Hepatitis C virus accumulates on mitochondria and renders the cells prone to undergoing mitochondria-mediated apoptosis. *J. Gen. Virol.* 87, 1935–1945.
- Pazienza, V., Clement, S., Pugnale, P., Conzelman, S., Foti, M., Mangia, A., and Negro, F. (2007). The hepatitis C virus core protein of genotypes 3a and 1b downregulates insulin receptor substrate 1 through genotype-specific mechanisms. *Hepatology* 45, 1164–1171.
- Poyndar, T., Yuen, M. F., Ratziu, V., and Lai, C. L. (2003). Viral hepatitis C. *Lancet* 362, 2095–2100.
- Rozance, P. J., Limesand, S. W., Barry, J. S., Brown, L. D., Thorn, S. R., LoTurco, D., Regnault, T. R., Friedman, J. E. and Hay, W. W. Jr. (2008). Chronic late-gestation hypoglycemia upregulates hepatic PEPCCK associated with increased PGC1alpha mRNA and phosphorylated CREB in fetal sheep. *Am. J. Physiol. Endocrinol. Metab.* 294, E365–E370.
- Shintani, Y., Fujie, H., Miyoshi, H., Tsutsumi, T., Tsukamoto, K., Kimura, S., Moriya, K., and Koike, K. (2004). Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance. *Gastroenterology* 126, 840–848.
- Takashima, M., Ogawa, W., Hayashi, K., Inoue, H., Kinoshita, S., Okamoto, Y., Sakaue, H., Wataoka, Y., Emi, A., Senga, Y., Matsuki, Y., Watanabe, E., Hiramatsu, R., and Kasuga, M. (2010). Role of KLF15 in regulation of hepatic gluconeogenesis and metformin action. *Diabetes* 59, 1608–1615.
- Tzivion, G., Dobson, M., and Ramakrishnan, G. (2011). FoxO transcription factors; Regulation by AKT and 14-3-3 proteins. *Biochim. Biophys. Acta* 1813, 1938–1945.
- van der Horst, A., and Burgering, B. M. (2007). Stressing the role of FoxO proteins in lifespan and disease. *Nat. Rev. Mol. Cell Biol.* 8, 440–450.
- Wakita, T., Pietschmann, T., Kato, T., Date, T., Miyamoto, M., Zhao, Z., Murthy, K., Habermann, A., Krausslich, H. G., Mizokami, M., Bartenschlager, R., and Liang, T. J. (2005). Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. *Nat. Med.* 11, 791–796.
- Wang, A. G., Lee, D. S., Moon, H. B., Kim, J. M., Cho, K. H., Choi, S. H., Ha, H. L., Han, Y. H., Kim, D. G., Hwang, S. B., and Yu, D. Y. (2009). Non-structural 5A protein of hepatitis C virus induces a range of liver pathology in transgenic mice. *J. Pathol.* 219, 253–262.
- Wu, X., and Freeze, H. H. (2002). GLUT14, a duplcon of GLUT3, is specifically expressed in testis as alternative splice forms. *Genomics* 80, 553–557.
- Zhao, X., Gan, L., Pan, H., Kan, D., Majeski, M., Adam, S. A., and Unterman, T. G. (2004). Multiple elements regulate nuclear/cytoplasmic shuttling of FOXO1: characterization of phosphorylation- and 14-3-3-dependent and -independent mechanisms. *Biochem. J.* 378, 839–849.

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Received: 01 December 2011; accepted: 25 December 2011; published online: 10 January 2012.

Citation: Shoji I, Deng L and Hotta H (2012) Molecular mechanism of hepatitis C virus-induced glucose metabolic disorders. *Front. Microbio.* 2:278. doi: 10.3389/fmicb.2011.00278

This article was submitted to *Frontiers in Virology*, a specialty of *Frontiers in Microbiology*.

Copyright © 2012 Shoji, Deng and Hotta. This is an open-access article distributed under the terms of the Creative Commons Attribution Non Commercial License, which permits non-commercial use, distribution, and reproduction in other forums, provided the original authors and source are credited.

A Point Mutation at Asn-534 That Disrupts a Conserved N-Glycosylation Motif of the E2 Glycoprotein of Hepatitis C Virus Markedly Enhances the Sensitivity to Antibody Neutralization

Mikiko Sasayama,¹ Ikuo Shoji,¹ Myrna Adianti,^{1,2} Da-Peng Jiang,¹ Lin Deng,¹ Takafumi Saito,³ Hisayoshi Watanabe,³ Sumio Kawata,³ Chie Aoki,^{1,4} and Hak Hotta^{1,4*}

¹Division of Microbiology, Center for Infectious Diseases, Kobe University Graduate School of Medicine, Kobe, Japan

²Institute of Tropical Disease, Airlangga University, Surabaya, Indonesia

³Faculty of Medicine, Department of Gastroenterology, Yamagata University, Yamagata, Japan

⁴Japan Science and Technology Agency (JST) / Japan International Cooperation Agency (JICA), SATREPS, Tokyo, Japan

The molecular basis of antibody neutralization against hepatitis C virus (HCV) is poorly understood. The E2 glycoprotein of HCV is critically involved in viral infectivity through specific binding to the principal virus receptor component CD81, and is targeted by anti-HCV neutralizing antibodies. A previous study showed that a mutation at position 534 (N534H) within the sixth N-glycosylation motif of E2 of the J6/JFH1 strain of HCV genotype 2a (HCV-2a) was responsible for more efficient access of E2 to CD81 so that the mutant virus could infect the target cells more efficiently. The purpose of this study was to analyze the sensitivity of the parental J6/JFH1, its cell culture-adapted variant P-47 possessing 10 amino acid mutations and recombinant viruses with the adaptive mutations to neutralization by anti-HCV antibodies in sera of HCV-infected patients. The J6/JFH1 virus was neutralized by antibodies in sera of patients infected with HCV-2a and -1b, with mean 50% neutralization titers being 1:670 and 1:200, respectively ($P < 0.00001$). On the other hand, the P-47 variant showed 50- to 200-times higher sensitivity to antibody neutralization than the parental J6/JFH1 without genotype specificity. The N534H mutation, and another one at position 416 (T416A) near the first N-glycosylation motif to a lesser extent, were shown to be responsible for the enhanced sensitivity to antibody neutralization. The present results suggest that the residues 534, and 416 to a lesser extent, of the E2 glycoprotein are critically involved in the HCV infectivity

and antibody neutralization. *J. Med. Virol.* **84:229–234, 2012.** © 2011 Wiley Periodicals, Inc.

KEY WORDS: humoral immune mechanism; evasion; glycan

INTRODUCTION

Hepatitis C virus (HCV), a member of the family *Flaviviridae*, the genus *Hepacivirus*, is an enveloped, positive-stranded RNA virus that infects an estimated 170 million people worldwide. The virus evades the

Grant sponsor: Science and Technology Research Partnership for Sustainable Development (SATREPS) Program of Japan Science and Technology Agency (JST) and Japan International Cooperation Agency (JICA); Grant sponsor: Japan Initiative for Global Research Network on Infectious Diseases (J-GRID) Program of Ministry of Education, Culture, Sports, Science and Technology, Japan; Grant sponsor: Research on Hepatitis, Health and Labour Sciences Research Grants of Ministry of Health, Labour and Welfare, Japan; Grant sponsor: Global Center of Excellence (G-COE) Program of Kobe University Graduate School of Medicine.

Mikiko Sasayama present address is Mahidol-Osaka Center for Infectious Diseases, Bangkok, Thailand.

*Correspondence to: Hak Hotta, MD, PhD, Division of Microbiology, Center for Infectious Diseases, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe 650-0017, Japan. E-mail: hotta@kobe-u.ac.jp

Accepted 7 September 2011

DOI 10.1002/jmv.22257

Published online in Wiley Online Library (wileyonlinelibrary.com).

host immune system to establish chronic infection, which often leads to serious liver diseases, such as cirrhosis and hepatocellular carcinoma. Even with a current standard treatment with pegylated interferon *plus* ribavirin, sustained viral clearance is obtained for only approximately 50% of patients infected with HCV genotype 1b (HCV-1b). Neither antibody-based prophylaxis nor an effective vaccine is currently available.

A better understanding of the interplay between viral and host factors that determine HCV clearance or persistence is needed for the design of effective passive immunotherapy and effective vaccines. A growing body of evidence from studies in humans and chimpanzees suggests that HCV-specific T-cell immunity plays an important role in the viral clearance [Bowen and Walker, 2005]. Also, several studies have indicated a role for humoral immunity in HCV infection [Bartosch et al., 2003; Logvinoff et al., 2004; Lavillette et al., 2005; Netski et al., 2005; Pestka et al., 2007; Dowd et al., 2009]. However, this aspect remains poorly characterized.

The E2 glycoprotein of HCV plays an important role in viral attachment and, therefore, becomes a major target of anti-HCV neutralizing antibodies. Identification of protective epitopes in E2 conserved among different HCV strains is a major challenge in vaccine design [Tarr et al., 2006; Helle et al., 2007; Gal-Tanamy et al., 2008; Keck et al., 2008]. The development of infectious retroviral pseudoparticles (HCVpp) bearing HCV envelope glycoproteins helps us study interactions between E2 epitopes and the virus receptor CD81 or neutralizing antibodies [Bartosch et al., 2003; Logvinoff et al., 2004; Lavillette et al., 2005; Pestka et al., 2007; Dowd et al., 2009]. More significantly, authentic HCV particles produced by the HCV cell culture system (HCVcc) are currently available for this purpose [Lindenbach et al., 2005; Wakita et al., 2005; Zhong et al., 2005; Fournier et al., 2007].

Recently, it was demonstrated using HCVcc that a mutation at position 534 from Asn to His (N534H) in the E2 glycoprotein of the HCV J6/JFH1 strain confers an advantage to the mutant viruses at the entry level probably through more efficient access to CD81 [Bungyoku et al., 2009]. The Asn-534 is located in the sixth of 11 *N*-linked glycosylation sites and the N534H mutation is predicted to remove this glycosylation. The present study has shown that the N534H mutation in the E2 glycoprotein of HCV J6/JFH1 markedly enhances the sensitivity of the virus to neutralization by specific neutralizing antibodies in sera of patients infected with HCV.

MATERIALS AND METHODS

Cells and Viruses

Huh-7.5 cells [Blight et al., 2002] and pFL-J6/JFH1 [Lindenbach et al., 2005] were kindly provided by

Dr. C. M. Rice (Rockefeller University, New York, NY, USA). Huh-7.5 cells were cultured in Dulbecco's modified Eagle's medium (DMEM; Wako, Osaka, Japan) supplemented with 10% fetal bovine serum (Biowest, Nuaille, France), 0.1 mM non-essential amino acids (Invitrogen, Carlsbad, CA), penicillin (100 IU/ml), and streptomycin (100 μ g/ml) (Invitrogen) at 37°C in a CO₂ incubator. Propagation of HCV J6/JFH1, its cell culture-adapted mutant P-47 and recombinant viruses possessing each of the adaptive mutations was described previously [Deng et al., 2008; Bungyoku et al., 2009].

Human Sera and Anti-HCV Neutralization Test

Sera were collected from 89 patients infected chronically with HCV-1b or HCV-2a, who were treated with pegylated interferon α -2b and ribavirin, as described previously [El-Shamy et al., 2007, 2008]. Sera were also collected from 11 patients with acute HCV-1b infection, either severe acute hepatitis or mild self-resolving hepatitis. The study protocol was approved by the Ethic Committees in Kobe University and Yamagata University and informed written consent provided by patients and volunteers. Sera collected from healthy volunteers who were negative for anti-HCV antibodies served as a control. The sera were inactivated at 56°C for 30 min before being used for the virus neutralization test.

An HCV neutralization test was performed as described previously [Sasayama et al., 2010]. In brief, serially diluted serum samples were mixed with the same amount of HCV solution containing 1×10^4 cell-infecting units. After incubation at 37°C for 1 hr, the mixtures were inoculated to Huh-7.5 cells (2×10^5 cells per well in 24-well plates) and incubated in a 5% CO₂ incubator. After 3 hr, the inocula were removed and fresh complete DMEM were added to the cells. At 24 hr postinfection, cells were fixed with ice-cold methanol, blocked with 5% goat serum in phosphate-buffered saline and subjected to immunofluorescence analysis using mouse monoclonal antibody against HCV core antigen (2H9) [Wakita et al., 2005] and Alexa Fluor 488-conjugated goat anti-mouse IgG (H + L) (Molecular Probes, Eugene, OR). The immunostained cells were counterstained with Hoechst 33342 (Molecular Probes) at room temperature for 5 min and observed under a fluorescence microscope (BZ-9000; Keyence, Osaka, Japan). The number of HCV-infected cells in each well was counted by using a software BZ-H1C (Keyence). The serum dilutions that neutralized 50% of the virus infectivity was calculated by curvilinear regression analysis [Abe et al., 2003]. Titers were expressed as 50% neutralization titers (NT₅₀).

Statistical Analysis

Student's *t*-test was used to compare the data between different groups. A *P*-value of <0.05 was considered to be significant.

RESULTS

Anti-HCV Neutralizing Antibodies in Sera of Patients Infected With HCV

Sera were obtained from patients chronically infected with HCV-1b or -2a, and tested for anti-HCV neutralizing activities. Representative results of neutralization curves using the parental J6/JFH1 and the P-47 mutant as challenge viruses are shown in Figure 1. When measured against J6/JFH1, NT₅₀ titers of sera of patients infected with HCV-1b ranged from 1:10 to 1:700, with the mean NT₅₀ titer being 1:197, whereas those of patients infected with HCV-2a ranged from 1:100 to 1:1,500, with the mean value being 1:670 (Table I). The difference in NT₅₀ between patients infected with HCV-1b and -2a was statistically significant ($P < 0.00001$). When measured against P-47, on the other hand, unexpectedly high NT₅₀ titers were obtained ranging from 1:4,000 to 1:182,000, with the mean values being 1:40,500 and 1:32,900 for patients infected with HCV-1b and -2a, respectively. These results suggest the possibility that an adaptive mutation(s) of P-47, most probably present in the envelope glycoproteins, confers higher sensitivity to neutralization by anti-HCV antibodies.

Unlike the case with J6/JFH1, when P-47 was used as a challenge virus, no significant difference in NT₅₀ titers was observed between patients infected with HCV-1b and -2a (Table I). This result suggests the possible presence of a genotype-dominant neutralization epitope(s) on the envelope glycoproteins of J6/JFH1 although anti-HCV neutralizing antibodies in patients' sera are reactive to both HCV-1b and -2a. The broad reactivity of the neutralizing antibodies in patients' sera across different HCV genotypes is consistent with previous observations by other researchers [Logvinoff et al., 2004; Meunier et al., 2005; Fournier et al., 2007; Pestka et al., 2007; Scheel et al., 2008].




Fig. 1. Neutralization curves (NT₅₀ assay) of sera obtained from HCV-infected patients against HCV J6/JFH1 and its adaptive mutant P-47. J6/JFH1 or P-47 was incubated with serial dilutions of HCV-infected patients (nos. 10, 23, and 42; all infected with HCV-1b) and tested for neutralization activities. The neutralization rates at each dilution were plotted. Filled and open symbols indicate data obtained with J6/JFH1 and P-47, respectively.

Sera obtained from patients with acute hepatitis C contained much lower titers of anti-HCV neutralizing antibodies compared to those in sera from chronic hepatitis patients, with the average NT₅₀ titers against J6/JFH1 and the adaptive mutant P-47 being 1:15 and 1:126, respectively (Table I). Two patients with severe acute hepatitis C with elevated serum alanine aminotransferase levels of $>1,000$ IU/ml [Saito et al., 2004; unpublished], possessed relatively high NT₅₀ titers against P-47 (1:150 and 1:1,100) compared to the remaining nine patients who experienced mild self-resolving hepatitis ($<1:10$ to 1:50).

A Single-Point Mutation (N534H or T416A) of the HCV E2 Glycoprotein Increases Sensitivity to Neutralization by Anti-HCV Antibodies

Neutralization of virus infectivity by antibodies usually involves their interaction with viral envelope glycoproteins. It has been reported that the cell culture-adapted mutant P-47 possesses 10 amino acid mutations, including four mutations in E2, compared to the parental J6/JFH1 [Bungyoku et al., 2009]. To examine which mutation(s) in E2 is responsible for the increased sensitivity of P-47 to neutralization by antibodies in patients' sera, recombinant viruses possessing each one of the four mutations in E2 were used (Fig. 2A). The result obtained revealed that a recombinant virus possessing a single-point mutation at position 534 from Asn to His (N534H) and another one possessing four mutations (E2) were as sensitive as P-47 to neutralization by sera of chronic hepatitis patients (Fig. 2B) and the two patients with acute hepatitis C (data not shown). The T416A and T396A mutants were also significantly more sensitive than J6/JFH1, but less sensitive than P-47, N534H, and E2 mutants, to neutralization by antibodies in patients' sera. In this connection, it was recently reported that a JFH1 virus-based T416A mutant showed increased sensitivity to antibody neutralization [Dhillon et al., 2010].

DISCUSSION

The present results revealed that sera of patients infected with HCV-1b possessed cross-genotypic neutralizing antibodies against the J6/JFH1 strain of HCV-2a, albeit with significantly lower titers (ca. one-third) compared to the homotypic neutralization titers observed for patients infected with HCV-2a (Table I). When measured against the adaptive mutant P-47 derived from J6/JFH1, neutralizing antibody titers of the patients sera increased markedly to the level 50- to 200-times higher than that measured against J6/JFH1. Also, the partial genotype-specificity observed with J6/JFH1 was no longer evident when measured against P-47. The marked increase in the sensitivity of P-47 to antibody neutralization was assigned to a mutation at position 534 (N534H), and another one at position 416 (T416A) to a lesser extent, of the E2 glycoprotein (Fig. 2).

TABLE I. NT₅₀ Titers in Sera of HCV-Infected Patients With Chronic or Acute Hepatitis C

CH/AH	Genotype	NT ₅₀ titer ^a measured against	
		J6/JFH1	P-47
CH	HCV-1b (n = 69)	197 ± 164 (1)	40,500 ± 31,800 (206)
CH	HCV-2a (n = 20)	670 ± 652 ^b (3.4)	32,900 ± 26,500 ^c (167)
AH	HCV-1b (n = 11)	15 ± 28 (0.08) (<10–100)	126 ± 326 (0.6) (<10–1,100)

CH, chronic hepatitis; AH, acute hepatitis.

^aMean ± SD. The number in the parenthesis means the ratio when compared to the mean titer that was obtained with sera of HCV-1b-infected CH patients against J6/JFH1.

^b*P* < 0.00001, compared to the mean titer obtained with sera of HCV-1b-infected patients against J6/JFH1 (Student's *t*-test).

^c*P* = 0.33, compared to the mean titer obtained with sera of HCV-1b-infected patients against P-47 (Student's *t*-test).

The N534H and T416A mutations are located at the sixth, and in close proximity to the first, respectively, of the conserved 11 *N*-linked glycosylation sites of the HCV E2 glycoprotein [Helle et al., 2007; Bungyoku et al., 2009]. It was recently reported that the positions 416 and 534 are conformationally located in the former and the latter halves of the central domain 1 (DIa and DIb), respectively, of E2 and that the two parts of DI domain interact to form the CD81-binding region [Helle et al., 2010; Krey et al., 2010; Albecka et al., 2011]. This region is, therefore, considered as the possible target for neutralizing antibodies that inhibit E2-CD81 interactions [Helle and Dubuisson,

2008; Law et al., 2008; Owsianka et al., 2008; Perotti et al., 2008].

The N534H mutation removes glycans at this position as it disrupts the consensus sequence for *N*-linked glycosylation. The removal of glycans at positions 417, 532, and 645 (the first, sixth, and eleventh glycosylation site, respectively) of the H77 isolate (HCV-1a) was shown to increase the sensitivity of HCVpp to neutralizing antibodies and to enhance the access of CD81 to its binding site on E2 [Falkowska et al., 2007; Helle et al., 2007]. It should be noted, however, that the HCVpp system relies on retroviral pseudoparticles bearing HCV envelope glycoproteins that assemble at the plasma membrane or in multivesicular bodies whereas HCV virions assemble on the endoplasmic reticulum membranes that are closely associated with lipid droplet [Miyanari et al., 2007; Helle and Dubuisson, 2008]. Therefore, the virus neutralization data obtained with HCVpp should be verified using the HCVcc system in which virion assembly and maturation take place through the authentic process.

By using the HCVcc system, it was shown that a variant virus possessing the N534K mutation spread faster than the parental JFH1 virus [Delgrange et al., 2007], with the result suggesting the possibility that removal of glycans on residue 534 resulted in more efficient access of E2 to CD81. It is also possible that removal of glycans on this residue might allow more efficient access of neutralizing antibodies to the CD81-binding region of E2, resulting in increased sensitivity to antibody neutralization. In fact, Helle et al. [2010] recently reported that removal of glycans at five (the first, second, fourth, sixth, and eleventh) *N*-linked glycosylation sites in E2 markedly increased the sensitivity of JFH1 virus to antibody neutralization, suggesting that the glycans interfere with the access of neutralizing antibodies to a determinant crucial for virus infectivity. It was also reported that mutations at positions 415 (N415D) and 416 (T416A) near the first glycosylation site of JFH1 virus increased the sensitivity to neutralizing antibodies in patients' sera [Dhillon et al., 2010]. Also, a mutation at position 451 (G451R), which is located in the domain 2 (DII) but still in close proximity to DI [Helle et al., 2010; Krey et al., 2010; Albecka et al., 2011],




Fig. 2. Effects of amino acid mutations at positions 396, 416, 534, and 712 of the HCV E2 glycoprotein on neutralization by anti-HCV antibodies in patients' sera. **A**: A schematic diagram of the mutations seen in the adaptive mutant P-47 and recombinant viruses carrying each (T396A, T416A, N534H, and A712V) and all (E2) of the four mutations in E2. Filled circles indicate the positions of the mutations. **B**: A representative result of virus neutralization by anti-HCV antibodies in an HCV-infected patient (no. 10; HCV-1b).

increased the sensitivity of JFH1 virus to antibody neutralization [Grove et al., 2008].

In conclusion, the present study using J6/JFH1 virus, another HCVcc strain, has demonstrated that the N534H mutation within the sixth *N*-glycosylation site of the E2 glycoprotein, and the T416A mutation near the first *N*-glycosylation site to a lesser extent, markedly enhances sensitivity to neutralization by antibodies in sera of HCV-infected patients. These results suggest that glycans on Asn-534 of the HCV E2 glycoprotein plays an important role in protecting the virus from humoral immune mechanisms of the host.

ACKNOWLEDGMENTS

We are grateful to Dr. C.M. Rice (Center for the Study of Hepatitis C, the Rockefeller University, New York, NY, USA) for providing pFL-J6/JFH1 and Huh-7.5 cells.

REFERENCES

- Abe M, Kuzuhara S, Kino Y. 2003. Establishment of an analyzing method for a Japanese encephalitis virus neutralization test in vero cells. *Vaccine* 21:1989–1994.
- Albecka A, Monserrret R, Krey T, Tarr AW, Diesis E, Ball JK, Descamps V, Duverlie G, Rey F, Penin F, Dubuisson J. 2011. Identification of new functional regions in hepatitis C virus envelope glycoprotein E2. *J Virol JVI accepts*, 85:1777–1792.
- Bartosch B, Bukh J, Meunier JC, Granier C, Engle RE, Blackwelder WC, Emerson SU, Cosset FL, Purcell RH. 2003. In vitro assay for neutralizing antibody to hepatitis C virus: Evidence for broadly conserved neutralization epitopes. *Proc Natl Acad Sci USA* 100:14199–14204.
- Blight KJ, McKeating JA, Rice CM. 2002. Highly permissive cell lines for subgenomic and genomic hepatitis C virus RNA replication. *J Virol* 76:13001–13014.
- Bowen DG, Walker CM. 2005. Adaptive immune responses in acute and chronic hepatitis C virus infection. *Nature* 436:946–952.
- Bungyoku Y, Shoji I, Makine T, Adachi T, Hayashida K, Nagano-Fujii M, Ide YH, Deng L, Hotta H. 2009. Efficient production of infectious hepatitis C virus with adaptive mutations in cultured hepatoma cells. *J Gen Virol* 90:1681–1691.
- Delgrange D, Pillez A, Castelain S, Cocquerel L, Rouillé Y, Dubuisson J, Wakita T, Duverlie G, Wychowski C. 2007. Robust production of infectious viral particles in Huh-7 cells by introducing mutations in hepatitis C virus structural proteins. *J Gen Virol* 88:2495–2503.
- Deng L, Adachi T, Kitayama K, Bungyoku Y, Kitazawa S, Ishido S, Shoji I, Hotta H. 2008. Hepatitis C virus infection induces apoptosis through a Bax-triggered, mitochondrion-mediated, caspase 3-dependent pathway. *J Virol* 82:10375–10385.
- Dhillon S, Witteveldt J, Gatherer D, Owsianka AM, Zeisel MB, Zahid MN, Rychłowska M, Fong SK, Baumert TF, Angus AG, Patel AH. 2010. Mutations within a conserved region of the hepatitis C virus glycoprotein that influence virus-receptor interaction and sensitivity to neutralizing antibodies. *J Virol* 84:5494–5507.
- Dowd KA, Netski DM, Wang XH, Cox AL, Ray SC. 2009. Selection pressure from neutralizing antibodies drives sequence evolution during acute infection with hepatitis C virus. *Gastroenterology* 136:2377–2386.
- El-Shamy A, Sasayama M, Nagano-Fujii M, Sasase N, Imoto S, Kim SR, Hotta H. 2007. Prediction of efficient virological response to pegylated interferon/ribavirin combination therapy by NS5A sequences of hepatitis C virus and anti-NS5A antibodies in pre-treatment sera. *Microbiol Immunol* 51:471–482.
- El-Shamy A, Nagano-Fujii M, Sasase N, Imoto S, Kim SR, Hotta H. 2008. Sequence variation in hepatitis C virus nonstructural protein 5A predicts clinical outcome of pegylated interferon/ribavirin combination therapy. *Hepatology* 48:38–47.
- Falkowska E, Kajumo F, Garcia E, Reinus J, Dragic T. 2007. Hepatitis C virus envelope glycoprotein E2 glycans modulate entry, CD81 binding, and neutralization. *J Virol* 81:8072–8079.
- Fournier C, Duverlie G, François C, Schnuriger A, Dedeurwaerder S, Brochet E, Capron D, Wychowski C, Thibault V, Castelain S. 2007. A focus reduction neutralization assay for hepatitis C virus neutralizing antibodies. *Virol J* 4:35.
- Gal-Tanamy M, Keck ZY, Yi M, McKeating JA, Patel AH, Fong SK, Lemon SM. 2008. In vitro selection of a neutralization-resistant hepatitis C virus escape mutant. *Proc Natl Acad Sci USA* 105:19450–19455.
- Grove J, Nielsen S, Zhong J, Bassendine MF, Drummer HE, Balfe P, McKeating JA. 2008. Identification of a residue in hepatitis C virus E2 glycoprotein that determines scavenger receptor BI and CD81 receptor dependency and sensitivity to neutralizing antibodies. *J Virol* 82:12020–12029.
- Helle F, Dubuisson J. 2008. Hepatitis C virus entry into host cells. *Cell Mol Life Sci* 65:100–112.
- Helle F, Goffard A, Morel V, Duverlie G, McKeating J, Keck ZY, Fong S, Penin F, Dubuisson J, Voisset C. 2007. The neutralizing activity of anti-hepatitis C virus antibodies is modulated by specific glycans on the E2 envelope protein. *J Virol* 81:8101–8111.
- Helle F, Vieyres G, Elkrief L, Popescu CI, Wychowski C, Descamps V, Castelain S, Roingeard P, Duverlie G, Dubuisson J. 2010. Role of N-linked glycans in the functions of hepatitis C virus envelope proteins incorporated into infectious virions. *J Virol* 84:11905–11915.
- Keck ZY, Olson O, Gal-Tanamy M, Xia J, Patel AH, Dreux M, Cosset FL, Lemon SM, Fong SK. 2008. A point mutation leading to hepatitis C virus escape from neutralization by a monoclonal antibody to a conserved conformational epitope. *J Virol* 82:6067–6072.
- Krey T, d'Alayer J, Kikuti CM, Saulnier A, Damier-Piolle L, Petitpas I, Johansson DX, Tawar RG, Baron B, Robert B, England P, Persson MA, Martin A, Rey FA. 2010. The disulfide bonds in glycoprotein E2 of hepatitis C virus reveal the tertiary organization of the molecule. *PLoS Pathog* 6:e1000762.
- Lavillette D, Morice Y, Germanidis G, Donot P, Soulier A, Pagkalos E, Sakellariou G, Intrator L, Bartosch B, Pawlotsky JM, Cosset FL. 2005. Human serum facilitates hepatitis C virus infection, and neutralizing responses inversely correlate with viral replication kinetics at the acute phase of hepatitis C virus infection. *J Virol* 79:6023–6034.
- Law M, Maruyama T, Lewis J, Giang E, Tarr AW, Stamataki Z, Gastaminza P, Chisari FV, Jones IM, Fox RI, Ball JK, McKeating JA, Kneteman NM, Burton DR. 2008. Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge. *Nat Med* 14:25–27.
- Lindenbach BD, Evans MJ, Syder AJ, Wölk B, Tellinghuisen TL, Liu CC, Maruyama T, Hynes RO, Burton DR, McKeating JA, Rice CM. 2005. Complete replication of hepatitis C virus in cell culture. *Science* 309:623–626.
- Logvinoff C, Major ME, Oldach D, Heyward S, Talal A, Balfe P, Feinstone SM, Alter H, Rice CM, McKeating JA. 2004. Neutralizing antibody response during acute and chronic hepatitis C virus infection. *Proc Natl Acad Sci USA* 101:10149–10154.
- Meunier JC, Engle RE, Faulk K, Zhao M, Bartosch B, Alter H, Emerson SU, Cosset FL, Purcell RH, Bukh J. 2005. Evidence for cross-genotype neutralization of hepatitis C virus pseudo-particles and enhancement of infectivity by apolipoprotein C1. *Proc Natl Acad Sci USA* 102:4560–4565.
- Miyazawa Y, Atsuzawa K, Usuda N, Watashi K, Hishiki T, Zayas M, Bartenschlager R, Wakita T, Hijikata M, Shimotohno K. 2007. The lipid droplet is an important organelle for hepatitis C virus production. *Nat Cell Biol* 9:1089–1097.
- Netski DM, Mosbrugger T, Depla E, Maertens G, Ray SC, Hamilton RG, Roundtree S, Thomas DL, McKeating J, Cox A. 2005. Humoral immune response in acute hepatitis C virus infection. *Clin Infect Dis* 41:667–675.
- Owsianka AM, Tarr AW, Keck ZY, Li TK, Witteveldt J, Adair R, Fong SK, Ball JK, Patel AH. 2008. Broadly neutralizing human monoclonal antibodies to the hepatitis C virus E2 glycoprotein. *J Gen Virol* 89:653–659.
- Perotti M, Mancini N, Diotti RA, Tarr AW, Ball JK, Owsianka A, Adair R, Patel AH, Clementi M, Burioni R. 2008. Identification of a broadly cross-reacting and neutralizing human monoclonal

- antibody directed against the hepatitis C virus E2 protein. *J Virol* 82:1047–1052.
- Pestka JM, Zeisel MB, Bläser E, Schürmann P, Bartosch B, Cosset FL, Patel AH, Meisel H, Baumert J, Viazov S, Rispeter K, Blum HE, Roggendorf M, Baumert TF. 2007. Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis C. *Proc Natl Acad Sci USA* 104:6025–6030.
- Saito T, Watanabe H, Shao L, Okumoto K, Hattori E, Sanjo M, Misawa K, Suzuki A, Takeda T, Sugahara K, Ito JI, Saito K, Togashi H, Kawata S. 2004. Transmission of hepatitis C virus quasispecies between human adults. *Hepatology* 39:57–62.
- Sasayama M, Deng L, Kim SR, Ide Y, Shoji I, Hotta H. 2010. Analysis of neutralizing antibodies against hepatitis C virus in patients who were treated with pegylated-interferon plus ribavirin. *Kobe J Med Sci* 56:E60–E66.
- Scheel TK, Gottwein JM, Jensen TB, Prentoe JC, Hoegh AM, Alter HJ, Eugen-Olsen J, Bukh J. 2008. Development of JFH1-based cell culture systems for hepatitis C virus genotype 4a and evidence for cross-genotype neutralization. *Proc Natl Acad Sci USA* 105:997–1002.
- Tarr AW, Owsianka AM, Timms JM, McClure CP, Brown RJ, Hickling TP, Pietschmann T, Bartenschlager R, Patel AH, Ball JK. 2006. Characterization of the hepatitis C virus E2 epitope defined by the broadly neutralizing monoclonal antibody AP33. *Hepatology* 43:592–601.
- Wakita T, Pietschmann T, Kato T, Date T, Miyamoto M, Zhao Z, Murthy K, Habermann A, Kräusslich HG, Mizokami M, Bartenschlager R, Liang TJ. 2005. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. *Nat Med* 11:791–796.
- Zhong J, Gastaminza P, Cheng G, Kapadia S, Kato T, Burton DR, Wieland SF, Uprichard SL, Wakita T, Chisari FV. 2005. Robust hepatitis C virus infection in vitro. *Proc Natl Acad Sci USA* 102:9294–9299.

Hepatitis C Virus Infection Promotes Hepatic Gluconeogenesis through an NS5A-Mediated, FoxO1-Dependent Pathway[∇]

Lin Deng,¹ Ikuo Shoji,¹ Wataru Ogawa,² Shusaku Kaneda,¹ Tomoyoshi Soga,³ Da-peng Jiang,¹ Yoshi-Hiro Ide,¹ and Hak Hotta^{1*}

Division of Microbiology, Center for Infectious Diseases,¹ and Division of Diabetes, Metabolism and Endocrinology,² Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe 650-0017, Japan, and Institute for Advanced Biosciences, Keio University, 246-2 Mizukami, Kakuganji, Tsuruoka, Yamagata 997-0052, Japan³

Received 21 January 2011/Accepted 7 June 2011

Chronic hepatitis C virus (HCV) infection is often associated with type 2 diabetes. However, the precise mechanism underlying this association is still unclear. Here, using Huh-7.5 cells either harboring HCV-1b RNA replicons or infected with HCV-2a, we showed that HCV transcriptionally upregulated the genes for phosphoenolpyruvate carboxykinase (PEPCK) and glucose 6-phosphatase (G6Pase), the rate-limiting enzymes for hepatic gluconeogenesis. In this way, HCV enhanced the cellular production of glucose 6-phosphate (G6P) and glucose. PEPCK and G6Pase gene expressions are controlled by the transcription factor forkhead box O1 (FoxO1). We observed that although neither the mRNA levels nor the protein levels of FoxO1 expression were affected by HCV, the level of phosphorylation of FoxO1 at Ser319 was markedly diminished in HCV-infected cells compared to the control cells, resulting in an increased nuclear accumulation of FoxO1, which is essential for sustaining its transcriptional activity. It was unlikely that the decreased level of FoxO1 phosphorylation was mediated through Akt inactivation, as we observed an increased phosphorylation of Akt at Ser473 in HCV-infected cells compared to control cells. By using specific inhibitors of c-Jun N-terminal kinase (JNK) and reactive oxygen species (ROS), we demonstrated that HCV infection induced JNK activation via increased mitochondrial ROS production, resulting in decreased FoxO1 phosphorylation, FoxO1 nuclear accumulation, and, eventually, increased glucose production. We also found that HCV NS5A mediated increased ROS production and JNK activation, which is directly linked with the FoxO1-dependent increased gluconeogenesis. Taken together, these observations suggest that HCV promotes hepatic gluconeogenesis through an NS5A-mediated, FoxO1-dependent pathway.

Hepatitis C virus (HCV) is a small, enveloped RNA virus that belongs to the genus *Hepacivirus* of the family *Flaviviridae*, and the molecular mechanisms underlying its viral replication are currently being unraveled (40). The HCV genome encodes a single polyprotein of about 3,000 amino acids, which is cleaved by host and viral proteases to generate at least 10 viral proteins, such as core, envelope 1 (E1), E2, p7, NS2, NS3, NS4A, NS4B, NS5A, and NS5B. HCV can be classified into seven genotypes, with each genotype further classified into a number of subtypes, such as HCV-1a and HCV-1b (18, 24, 59).

HCV infects more than 120 million people worldwide (57). Persistent HCV infection causes not only liver diseases (chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma) but also extrahepatic manifestations, such as type 2 diabetes (2, 11, 20, 23). While it is known that liver cirrhosis impairs the glucose metabolism of the liver, there are some reports showing that HCV-infected patients over 40 years of age have an increased risk of type 2 diabetes compared with individuals without HCV infection (43). In addition, insulin receptor substrate 1 (IRS-1)/phosphatidylinositol 3-kinase (PI3-kinase) signaling was more impaired in HCV-infected

patients than in non-HCV-infected controls (3). These studies imply that HCV infection may directly predispose the host toward type 2 diabetes. However, the precise mechanisms are poorly understood.

Hepatocytes play an important role in maintaining plasma glucose homeostasis by adjusting the balance between hepatic glucose production and utilization via the gluconeogenic and glycolytic pathways, respectively. It was proposed previously that increased hepatic glucose production is a major feature of type 2 diabetes (13). It is also known that hyperglycemia and the subsequent development of type 2 diabetes mellitus result, at least in part, from impaired insulin signaling together with elevated glucagon levels (5, 19). Hepatic glucose production and utilization, physiologically opposed cascades, are regulated, at least in part, at the transcriptional level of the glucose 6-phosphatase (G6Pase) and glucokinase (GK) genes, which catalyze the last and the first rate-limiting steps in gluconeogenesis and glycolysis, respectively. A number of studies have shown that fasting/feeding (or hormones) controls the transcription of these two enzymes in the opposite directions. G6Pase transcription is negatively regulated by insulin or feeding and is markedly increased in a fasting state (62). On the other hand, GK transcription is positively regulated by insulin or feeding and markedly decreased in a fasting state (33). It has also been reported that the gene expressions of gluconeogenic and glycolytic enzymes, such as G6Pase, GK, and phosphoenolpyruvate carboxykinase (PEPCK), another rate-limiting enzyme for hepatic gluconeogenesis, are regulated by certain

* Corresponding author. Mailing address: Division of Microbiology, Center for Infectious Disease, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe 650-0017, Japan. Phone: 81-78-382-5500. Fax: 81-78-382-5519. E-mail: hotta@kobe-u.ac.jp.

[∇] Published ahead of print on 22 June 2011.

TABLE 1. Sequences and positions of primers used in this study

Gene (GenBank accession no.)	Primer	Positions	PCR product (bp)
GK (M69051)	5'-GCCTCCCAAAGCATCTACCTC-3' 5'-GCTCCACTGCCCTCCTCACC-3'	119–139 562–542	444
G6Pase (U01120)	5'-CCTGGGGCTGGCTCTCAACTC-3' 5'-AATAGTAGTCTCCTCAATCC-3'	889–909 1197–1177	309
PEPCK (BC023978)	5'-CCAGGCAGTGAGGGAGTTTCT-3' 5'-ACTGTGTCTCTTTGCTCTTGG-3'	210–230 426–406	217
FoxO1 (NM_002915)	5'-GAGGGTTAGTGAGCAGGTTAC-3' 5'-AGTCCTTATCTACAGCAGCAC-3'	2352–2372 2568–2548	217
HCV NS5A (JF343793)	5'-AGACGTATTGAGGTCCATGC-3' 5'-CCGCAGCGACGGTGCTGATAG-3'	6899–6918 7011–7031	133
β -Glucuronidase (M15182)	5'-ATCAAAAACGCAGAAAATACG-3' 5'-ACGCAGGTGGTATCAGTCTTG-3'	1747–1767 1984–1964	238
GAPDH (NM_002046)	5'-GCCATCAATGACCCCTTCATT-3' 5'-TCTCGCTCTGGAAGATGG-3'	196–216 326–344	149

transcription factors, including forkhead box O1 (FoxO1) (26, 50, 54), hepatic nuclear factor 4 α (HNF-4 α) (26), Krüppel-like factor 15 (KLF15) (64), and cyclic AMP (cAMP) response element binding protein (CREB) (52, 56). The deregulation of the otherwise balanced control of hepatic glucose homeostasis would potentially lead to hyperglycemia and, eventually, type 2 diabetes.

In this study, by using Huh-7.5 cells harboring HCV-1b RNA replicons, i.e., either a subgenomic RNA replicon (SGR) or a full-genomic RNA replicon (FGR) (37), and cells infected with HCV-2a (14, 37, 39), we investigated the possible effects of HCV on glucose metabolism. We report here that HCV promotes hepatic gluconeogenesis, resulting in increased cellular glucose production in hepatocytes via an NS5A-mediated, FoxO1-dependent pathway.

MATERIALS AND METHODS

Cells, HCV RNA replicons, and virus. The human hepatoma-derived cell line Huh-7.5 (7) was kindly provided by C. M. Rice (Rockefeller University, New York, NY). The SGR and FGR were prepared by using pFK5B/2884Gly (41) (a kind gift from R. Bartenschlager, University of Heidelberg, Heidelberg, Germany) and pON/C-5B (31) (a kind gift from N. Kato, Okayama University, Okayama, Japan), respectively. The SGR and FGR cells are of polyclonal origin to avoid clonal variation. Plasmid pFL-J6/JFH1, which encodes the entire viral genome of a chimeric strain of HCV-2a (J6/JFH1) (39), was kindly provided by C. M. Rice. The HCV RNA genome was transcribed *in vitro* from pFL-J6/JFH1 and transfected into Huh-7.5 cells to yield infectious HCV particles, as described previously (14). A cell culture-adapted P-47 strain (9, 14) was used throughout the experiments. Virus infection was performed at a multiplicity of infection (MOI) of 2.0. Virus infectivity was measured by indirect immunofluorescence analysis, as described below, and expressed as cell-infecting units/ml. In some experiments, SGR and FGR cells, as well as HCV-infected cells at 5 days after virus infection, were treated with 1,000 IU/ml of alpha interferon (IFN) (Sigma Chemical, St. Louis, MO) for 10 days to eliminate HCV replication.

Plasmid construction. Expression plasmids for core, p7, NS2, NS3, NS3/4A, NS4A, NS4B, NS5A, and NS5B were reported elsewhere previously (15, 32).

Real-time quantitative RT-PCR. Total cellular RNA was isolated by using RNAiso reagent (Takara, Kyoto, Japan), and cDNA was generated by using a QuantiTect reverse transcription (RT) system (Qiagen, Valencia, CA). Real-time quantitative PCR was performed by using SYBR Premix Ex Taq (Takara) with SYBR green chemistry on an ABI Prism 7000 system (Applied Biosystems, Foster City, CA), as reported previously (37). β -Glucuronidase and GAPDH

(glyceraldehyde-3-phosphate dehydrogenase) were used as internal controls. The primers used are shown in Table 1.

G6P production assay. Huh-7.5 cells seeded into a 10-cm dish at a density of 1.0×10^6 cells/dish were infected with HCV or left uninfected. At different time points after infection, the cells were washed twice with 5% mannitol solution and covered with methanol (1 ml) containing 25 μ M (each) four internal standards (3-aminopyridine, L-methionine sulfone, trimesate, and 2-morpholinoethanesulfonic acid) for enzyme inactivation. The mixtures of methanol and cells were collected and mixed with Milli-Q water and chloroform at ratios of 2:1:2. Both the medium and cell sample solutions were then centrifuged at $20,000 \times g$ for 15 min, and the aqueous layers were collected for centrifugal filtration through a 5-kDa-cutoff filter at $9,000 \times g$ for 2 h. The extracted metabolites were concentrated with a centrifugal concentrator and stored at -80°C until analysis. Glucose 6-phosphate (G6P) concentrations were measured by capillary electrophoresis time-of-flight mass spectrometry (CE-TOFMS), and the results were normalized to the cell number as described previously (60, 61).

Glucose production assay. Culture medium was replaced with glucose production buffer consisting of glucose-free Dulbecco's modified Eagle's medium (DMEM) (Sigma Chemical), without phenol red, supplemented with a gluconeogenic substrate (2 mM sodium pyruvate and 20 mM sodium lactate). After 24 h of incubation, the medium was collected, and the total glucose concentration was measured by using a commercial kit (Glucose CII Test Wako; Wako Pure Chemical Industries, Osaka, Japan) and normalized to the cellular protein content. As the baseline of glucose production, glucose-free DMEM with neither sodium pyruvate nor sodium lactate was used. Glucose production via gluconeogenesis equals the total glucose production minus the baseline glucose production.

Luciferase reporter assay. The PEPCK gene promoter (position $-1263/+225$) and a deletion mutant (position $-998/+225$) were inserted into the pGL3 luciferase reporter plasmid (Promega, Madison, WI). The constructs were designated rPEPCK-P5(-1263)-pGL3basic and rPEPCK-P4(-998)-pGL3basic. pRL-CMV-Renilla (Promega), which expresses *Renilla* luciferase, was used as an internal control. Huh-7.5 cells prepared in a 12-well tissue culture plate at a density of 1.0×10^5 cells/well were transiently transfected with pRL-CMV-Renilla and rPEPCK-P5(-1263)-pGL3basic or rPEPCK-P4(-998)-pGL3basic in the presence of pEF1/NS4A, pEF1/NS5A, or a control vector (32). After 48 h, a luciferase assay was performed by using the Dual-Luciferase reporter assay system (Promega). Firefly and *Renilla* luciferase activities were measured with a Lumat LB 9501 luminometer (Berthold, Bad Wildbad, Germany). Firefly luciferase activity was normalized to *Renilla* luciferase activity for each sample.

Detection of mitochondrial ROS. Mitochondrial reactive oxygen species (ROS) production was analyzed as described previously (14). Briefly, cells seeded onto glass coverslips in a 24-well plate were incubated with 5 μ M MitoSOX red (Molecular Probes, Eugene, OR) at 37°C for 10 min and then fixed with 3.7% paraformaldehyde and observed under a confocal laser scanning microscope (Carl Zeiss, Oberkochen, Germany). When needed, the fixed cells

were subjected to indirect immunofluorescence analysis to confirm HCV infection or NS5A expression, as described below.

Indirect immunofluorescence. Huh-7.5 cells seeded onto glass coverslips in a 24-well plate were infected with HCV or transfected with an NS5A expression plasmid. At 5 days postinfection (dpi) or 3 days posttransfection, the cells were fixed with 3.7% paraformaldehyde in phosphate-buffered saline (PBS) for 15 min at room temperature and permeabilized with 0.1% Triton X-100 in PBS for 15 min at room temperature. Mock-infected or empty-vector-transfected cells were similarly treated as controls for comparisons. After being washed with PBS twice, cells were consecutively stained with primary and secondary antibodies. The primary antibodies used were anti-FoxO1 rabbit monoclonal antibody (Cell Signaling Technology, Danvers, MA), anti-NS5A mouse monoclonal antibody (Chemicon International, Temecula, CA), and serum from an HCV-infected patient. Secondary antibodies used were Alexa Fluor 488-conjugated goat anti-rabbit immunoglobulin G (IgG), Alexa Fluor 594-conjugated goat anti-mouse IgG or anti-human IgG (Molecular Probes), and fluorescein isothiocyanate (FITC)-conjugated goat anti-mouse IgG or anti-human IgG (MBL, Nagoya, Japan). The stained cells were observed under a confocal laser scanning microscope (Carl Zeiss).

Cell fractionation and immunoblotting. Nuclear and cytoplasmic extracts from cells were prepared by using an NE-PER nuclear and cytoplasmic extraction reagent kit (Pierce Chemical, Rockford, IL). For immunoblotting, cells were lysed with SDS sample buffer, and equal amounts of protein were subjected to SDS-polyacrylamide gel electrophoresis and transferred onto a polyvinylidene difluoride membrane (Millipore, Bedford, MA), which was then incubated with the respective primary antibodies. The primary antibodies used were mouse monoclonal antibodies against HCV core (clone 2H9; a kind gift from T. Wakita, Department of Virology II, National Institute of Infectious Diseases, Tokyo, Japan), NS3, NS4A, NS5A, GAPDH (Chemicon), FoxO1 (Sigma Chemical), phospho-Akt (Ser473) (Cell Signaling Technology), and c-Myc (9E10; Santa Cruz Biotechnology, Santa Cruz, CA); rabbit polyclonal antibodies against phospho-FoxO1 (Ser139), Oct-1 (Santa Cruz Biotechnology), c-Jun N-terminal kinase (JNK), phospho-JNK (Thr183/Tyr185), c-Jun, phospho-c-Jun (Ser63), and Akt (Cell Signaling Technology); and goat polyclonal antibody against HSP60 (Santa Cruz Biotechnology). Horseradish peroxidase-conjugated goat anti-mouse IgG, goat anti-rabbit IgG (Molecular Probes), and donkey anti-goat IgG (Santa Cruz Biotechnology) were used to visualize the respective proteins by means of an enhanced chemiluminescence detection system (ECL; GE Healthcare, Buckinghamshire, United Kingdom).

Statistical analysis. Results were expressed as means \pm standard errors of the means (SEM). Statistical significance was evaluated by analysis of variance (ANOVA) and was defined as a *P* value of <0.05 .

RESULTS

HCV upregulates gene expression of PEPCK and G6Pase and downregulates gene expression of GK. We first examined the expression levels of the genes for the rate-limiting enzymes in hepatic gluconeogenesis, PEPCK and G6Pase, and of those for GK, which catalyzes the first step of glycolysis, by means of real-time quantitative RT-PCR analysis. We observed that the PEPCK and G6Pase genes were transcriptionally activated in SGR- and FGR-harboring cells (Fig. 1A and B, left). Similarly, the PEPCK and G6Pase genes were upregulated in HCV-infected cells in a time-dependent manner, starting from 3 or 5 days postinfection (dpi) up to 14 dpi (Fig. 1A and B, middle). On the other hand, the GK gene was transcriptionally downregulated in SGR- and FGR-harboring cells and HCV-infected cells in a time-dependent manner (Fig. 1C). It is noteworthy that the gene expressions of six glycolytic enzymes (not including GK) were observed to be upregulated in HCV-infected cells at 1 dpi (16).

When IFN treatment eliminated HCV from the cells, the observed upregulation of PEPCK and G6Pase gene expressions as well as the downregulation of GK gene expression in SGR- and FGR-harboring cells and HCV-infected cells were cancelled (Fig. 1A, B, and C, left and right). Thus, our results

suggest that there was a trend toward an increase in gluconeogenesis in SGR- and FGR-harboring cells and HCV-infected cells. In subsequent studies we further examined whether or not HCV replication was correlated with gluconeogenesis.

HCV promotes cellular production of glucose and G6P. We then examined the effect of HCV on cellular glucose production. The results showed that SGR- and FGR-harboring cells and HCV-infected cells produced greater amounts of glucose than did the control cells (Fig. 2A, top and middle). IFN treatment cancelled the enhanced glucose production in SGR- and FGR-harboring cells and in HCV-infected cells (Fig. 2A, top and bottom). We also investigated the production of G6P, which is an important precursor molecule that is converted to glucose in the gluconeogenesis pathway, by means of metabolome analysis. As shown in Fig. 2B, a significantly higher level of G6P was accumulated in HCV-infected cells than in control cells. Taken together, these results indicate that HCV indeed promotes hepatic gluconeogenesis to cause hyperglycemia. In the following analyses, we examined the possible mechanisms of HCV-induced increased gluconeogenesis.

HCV suppresses FoxO1 phosphorylation at Ser319, leading to the nuclear accumulation of FoxO1. It was demonstrated previously that FoxO1 in hepatocytes enhances gluconeogenesis through the transcriptional activation of various genes, including G6Pase and PEPCK (25). To investigate the possible effects of FoxO1 on HCV-induced gluconeogenesis, we examined the gene expression levels of FoxO1 by real-time quantitative RT-PCR analysis. As shown in Fig. 3A, there was neither an upregulation nor a downregulation of FoxO1 gene expression in SGR- or FGR-harboring cells or HCV-infected cells. The FoxO1 transcription factor is controlled by various post-translational modifications, which include phosphorylation, ubiquitylation, and acetylation. The phosphorylated form of FoxO1 is exported from the nucleus and thereby loses its transcriptional function (30). We therefore examined the phosphorylation status of FoxO1 at Ser319, which is critical for FoxO1 nuclear exclusion (72). The results showed that FoxO1 phosphorylation at Ser319 was markedly suppressed in HCV-infected cells from 4 dpi up to 8 dpi, compared to that in the HCV-negative control cells (Fig. 3B, first panel), in a time-dependent manner that was roughly the inverse of the pattern observed for PEPCK and G6Pase mRNA upregulations (Fig. 1A and B) and glucose production (Fig. 2A), while the total protein expression levels of FoxO1 were unchanged (Fig. 3B, second panel). Regarding this connection, Banerjee et al. reported previously that FoxO1 phosphorylation at Ser256 was also inhibited in HCV-infected cells (4). Since FoxO1 is known to be phosphorylated by Akt so as to be exported from the nucleus and transcriptionally inactivated (38), we examined whether Akt function was suppressed through its impaired phosphorylation in HCV-infected cells. The result obtained revealed that this was not the case: Akt phosphorylation was enhanced in HCV-infected cells from 4 dpi up to 6 dpi compared with the control cells (Fig. 3B, third panel), while the total protein expression levels of Akt were comparable (Fig. 3B, fourth panel). This result is consistent with a recent observation by Burdette et al. (10) showing that the Akt phosphorylation level was elevated in HCV-infected cells. These data suggest that the observed decrease in FoxO1 phosphorylation




FIG. 1. HCV upregulates gene expressions of PEPCK and G6Pase and downregulates gene expression of GK. Quantitative RT-PCR analysis was performed to quantify PEPCK (A), G6Pase (B), and GK (C) mRNA expression levels in SGR- and FGR-harboring cells and HCV-infected cells (MOI = 2), and the results were normalized to β -glucuronidase mRNA expression levels. In parallel, SGR- and FGR-harboring cells and HCV-infected cells (at 5 dpi) were treated with IFN (1,000 IU/ml) for 10 days to eliminate HCV replication before being subjected to quantitative RT-PCR. Data represent means \pm SEM of data from three independent experiments, and the values for the control cells were arbitrarily expressed as 1.0. *, $P < 0.01$ compared with the control.

in HCV-infected cells is caused by a mechanism independent of Akt.

Next, we tested whether HCV indeed promoted FoxO1 nuclear accumulation. The majority of FoxO1 was accumulated in the nuclear fraction in HCV-infected cells (Fig. 3C, second panel, lanes 2 and 4), whereas in control cells FoxO1 was distributed in both the nuclear and cytoplasmic fractions (lanes 1 and 3). Taken together, these results suggest that HCV suppressed FoxO1 phosphorylation, leading to the nuclear accumulation of FoxO1.

HCV-induced JNK activation is involved in the suppression of FoxO1 phosphorylation. Recent studies demonstrated that a signaling pathway that involves the stress-sensitive serine/threonine kinase JNK regulates FoxO at multiple levels (36, 66). We therefore investigated whether HCV induced JNK activation in Huh-7.5 cells. As shown in Fig. 4A, the amount of

phosphorylated (activated) JNK markedly increased in HCV-infected cells in a time-dependent manner, similar to that observed for the suppression of FoxO1 phosphorylation, while the total expression levels of JNK were unchanged. As a result, c-Jun, a key substrate for JNK, was phosphorylated (activated) in HCV-infected cells but not in the mock-infected control cells. It should also be noted that the total expression levels of c-Jun in HCV-infected cells were significantly higher than those in the mock-infected control cells, suggesting that c-Jun activation through its phosphorylation stabilizes c-Jun protein expression in HCV-infected cells, as was proposed previously by Zhang et al (71).

We next sought to determine whether JNK activation was involved in the HCV-induced suppression of FoxO1 phosphorylation. HCV-infected cells at 5 days after virus infection were treated with the specific JNK inhibitor SP600125 (20 μ M) (6)




FIG. 2. HCV promotes the production of glucose and G6P. (A) Extracellular glucose production was measured in SGR- and FGR-harboring cells and HCV-infected cells (MOI = 2) and normalized to total cellular protein expression levels. In parallel, SGR- and FGR-harboring cells and HCV-infected cells (at 5 dpi) were treated with IFN (1,000 IU/ml) for 10 days to eliminate HCV replication before being subjected to glucose production analysis. Data represent means \pm SEM of data from three independent experiments, and the value for the control cells was arbitrarily expressed as 1.0. *, $P < 0.01$ compared with the control. (B) Cellular G6Pase production was measured in HCV-infected cells (MOI = 2), and the results were normalized to cell numbers. Data represent means \pm SEM of data from three independent experiments. *, $P < 0.01$ compared with the control.




FIG. 3. HCV suppresses FoxO1 phosphorylation, leading to nuclear accumulation of FoxO1. (A) Quantitative RT-PCR analysis was performed to determine FoxO1 mRNA expression levels in SGR- and FGR-harboring cells and HCV-infected cells (MOI = 2), and expression levels were normalized to β -glucuronidase mRNA expression levels. (B) The expression levels of FoxO1, phospho-FoxO1 (Ser319) (P-FoxO1), Akt, and phospho-Akt (Ser473) were analyzed by immunoblotting of HCV-infected cells and mock-infected control cells. Blots were reprobbed with antibodies recognizing NS3 and GAPDH. The amounts of GAPDH were measured as an internal control to verify equal amounts of sample loading. (C) Cytoplasmic and nuclear fractions were prepared from HCV-infected cells and mock-infected control cells at 4 dpi and were analyzed by immunoblotting using antibodies against FoxO1, phospho-FoxO1 (Ser319), NS3, Hsp60, and Oct-1. The amounts of Hsp60 and Oct-1 were measured to verify that they were equal to the amounts of cytoplasmic and nuclear fractions, respectively.

for 24 h. The catalytic JNK activity was assayed by monitoring the phosphorylation of c-Jun. As shown in Fig. 4B, SP600125 clearly prevented the phosphorylation of c-Jun and concomitantly recovered the suppression of FoxO1 phosphorylation in




FIG. 4. HCV-induced JNK activation is required for the suppression of FoxO1 phosphorylation. (A) HCV activates the JNK/c-Jun signaling pathway. The activation (phosphorylation) of JNK (Thr183/Tyr185) and c-Jun (Ser63) in whole-cell lysates of HCV-infected cells and mock-infected control cells was analyzed by immunoblotting. Blots were reprobed with antibodies recognizing total JNK and c-Jun, NS3, and GAPDH. The amounts of GAPDH were measured as an internal control to verify equal amounts of sample loading. (B) Pretreatment with the JNK inhibitor SP600125 abrogates HCV-induced c-Jun activation and FoxO1 phosphorylation suppression. The phosphorylation of c-Jun (Ser63) and that of FoxO1 (Ser319) were analyzed by immunoblotting at 6 dpi in HCV-infected cells and mock-infected control cells with or without SP600125 pretreatment (20 μ M for 24 h). Blots were reprobed with antibodies recognizing total c-Jun and FoxO1, NS3, and GAPDH. The amounts of GAPDH were measured as an internal control to verify equal amounts of sample loading.

HCV-infected cells. These results suggest that HCV activates the JNK/c-Jun signaling pathway, which induces the nuclear accumulation of FoxO1 by reducing its phosphorylation status.

HCV-induced mitochondrial ROS production is involved in FoxO1 phosphorylation suppression, FoxO1 nuclear accumulation, and increased glucose production through JNK activation. We previously reported that HCV infection increases mitochondrial ROS production (14). JNK is known to be activated by ROS (35). We therefore sought to determine whether the HCV-induced increase in ROS production is an event occurring upstream of JNK activation by HCV. The pretreatment of HCV-infected cells (at 6 dpi) with 5 mM *N*-acetyl cysteine (NAC) (a general antioxidant) for 2 h significantly reduced the HCV-induced increase in ROS levels (Fig. 5A and B), as revealed by using MitoSOX, a fluorescent probe specific for superoxide that selectively accumulates in the mitochondrial compartment. As shown in Fig. 5C, NAC clearly prevented the phosphorylation of JNK and concomitantly recovered the suppression of FoxO1 phosphorylation in HCV-




FIG. 5. HCV-induced production of mitochondrial ROS suppresses FoxO1 phosphorylation through activation of JNK. (A) Pretreatment with NAC abrogates the HCV-induced increased production of mitochondrial ROS. HCV-infected cells and mock-infected controls were pretreated with 5 mM NAC for 2 h at 6 dpi. The cells were then incubated with MitoSOX (top) and then stained for HCV antigens by using serum from an HCV-infected patient, followed by FITC-conjugated goat anti-human IgG (bottom). (B) Quantification of MitoSOX-stained cells. The percentages of cells stained with MitoSOX were determined for HCV-infected cells and mock-infected controls with or without NAC pretreatment. Data represent means \pm SEM of data from two independent experiments. *, $P < 0.01$. (C) NAC pretreatment abrogates HCV-induced JNK activation and FoxO1 phosphorylation suppression. The phosphorylation of JNK (Thr183/Tyr185) and that of FoxO1 (Ser319) were analyzed by immunoblotting at 6 dpi in HCV-infected cells and mock-infected controls with or without NAC pretreatment (5 mM for 2 h). The blots were reprobed with antibodies recognizing total JNK and FoxO1, NS3, and GAPDH. The amounts of GAPDH were measured as an internal control to verify equal amounts of sample loading.

infected cells. These results suggest that HCV-induced ROS production is involved in JNK activation, which results in the inhibition of FoxO1 phosphorylation.

We next investigated the effects of JNK activation and ROS production on the subcellular localization of FoxO1 in HCV-infected cells by indirect immunofluorescence staining. As shown in Fig. 6A and B, FoxO1 was localized predominantly in the cytoplasm of mock-infected control cells. On the other




FIG. 6. HCV-induced JNK activation and ROS production are involved in FoxO1 nuclear accumulation and increased glucose production. (A) Subcellular localization of FoxO1 in HCV-infected cells and mock-infected controls with or without JNK inhibitor (SP600125 at 20 μ M for 24 h) or antioxidant (NAC at 5 mM for 2 h) pretreatment at 5 dpi was examined by confocal microscopy. After fixation and permeabilization, the cells were incubated with an anti-FoxO1 rabbit monoclonal antibody followed by Alexa Fluor 488-conjugated goat anti-rabbit IgG (top) and with serum from an HCV-infected patient followed by Alexa Fluor 594-conjugated goat anti-human IgG (bottom). (B) The percentages of cells with FoxO1 nuclear localization were determined for HCV-infected cells and mock-infected controls with or without SP600125 or NAC pretreatment. Data represent means \pm SEM of data from two independent experiments. *, $P < 0.01$. (C) Extracellular glucose production was measured in HCV-infected cells and mock-infected controls with or without SP600125 or NAC pretreatment at 7 dpi and normalized to total cellular protein expression levels. Data represent means \pm SEM of data from two independent experiments, and the value for the control cells was arbitrarily expressed as 1.0. *, $P < 0.01$. (D) Cellular expression levels of NS3 in HCV-infected cells and mock-infected control cells with or without sodium lactate (SL), sodium pyruvate (SP), SP600125, or NAC are shown. The amounts of GAPDH were measured as an internal control to verify equal amounts of sample loading. (E) Amounts of HCV RNA were measured by quantitative RT-PCR analysis of HCV-infected cells treated with SP600125 or NAC or left untreated at 6 dpi. The amounts were normalized to GAPDH mRNA expression levels. Data represent means \pm SEM of data from two independent experiments, and the value for the nontreated HCV-infected cells was arbitrarily expressed as 1.0. (F) Virus infectivity in the culture supernatants of HCV-infected cells treated with SP600125 or NAC or left untreated at 6 dpi was measured. Data represent means \pm SEM of data from two independent experiments. CIU, cell-infecting units.

hand, the nuclear accumulation of FoxO1 was clearly observed in approximately 35% of HCV-infected cells at 5 dpi. The treatment of HCV-infected cells with a JNK inhibitor (SP600125 at 20 μ M for 24 h) or an antioxidant (NAC at 5 mM for 2 h) significantly inhibited HCV-induced FoxO1 nuclear accumulation.

To further verify the role played by JNK activation and ROS production in HCV-induced hepatic gluconeogenesis, the glucose production in SP600125- or NAC-treated HCV-infected cells was assessed. Treatment with SP600125 or NAC significantly impaired the HCV-induced increased glucose production at 7 dpi (Fig. 6C) but did not affect the overall abundance

of the HCV NS3 protein (Fig. 6D). We also examined the possible effects of SP600125 or NAC on HCV RNA replication and infectious-virus production. The results obtained revealed that treatment with SP600125 (20 μ M for 24 h) or NAC (5 mM for 2 h) barely affected HCV RNA replication (Fig. 6E). On the other hand, we noted a tendency for infectious-virus production to be only slightly suppressed by SP600125 but not by NAC (Fig. 6F). A short-term inhibition of glucose production might not sufficiently affect HCV RNA replication or virus production.

Taken together, these results indicate that ROS-mediated JNK activation plays a key role in the suppression of FoxO1




FIG. 7. HCV NS5A is involved in increased mRNA expression levels for G6Pase and PEPCK. Huh-7.5 cells were transfected with the indicated HCV viral protein expression plasmids. (A and B) At 3 and 5 days posttransfection, quantitative RT-PCR analyses of mRNA for G6Pase (A) and PEPCK (B) were conducted, and the results were normalized to β -glucuronidase mRNA expression levels. Data represent means \pm SEM of data from three independent experiments, and the values for the control cells were arbitrarily expressed as 1.0. *, $P < 0.01$ compared with the control. (C) At 3 days posttransfection, the expression levels of each of the HCV proteins were examined by immunoblot analysis using antibodies against c-Myc, core, NS4A, and GAPDH. The amounts of GAPDH served as an internal control to verify equal amounts of sample loading. (D) NS5A and NS4A enhance PEPCK promoter activity. NS5A and NS4A expression plasmids were each cotransfected with rPEPCK-P5(-1263)-pGL3basic or rPEPCK-P4(-998)-pGL3basic in Huh-7.5 cells. At 48 h after transfection, the PEPCK promoter activities were measured by using a luciferase reporter assay. Data represent means \pm SEM of data from three independent experiments, and the values for the control cells were arbitrarily expressed as 1.0. *, $P < 0.05$ compared with the control.

phosphorylation, the nuclear accumulation of FoxO1, and the enhancement of glucose production in HCV-infected cells.

HCV NS5A is involved in the enhancement of glucose production. To examine which HCV protein(s) is involved in the enhancement of gluconeogenesis, expression constructs of each of the HCV viral proteins were transfected into Huh-7.5 cells, and the gene expression levels of PEPCK and G6Pase were examined by real-time quantitative RT-PCR analysis. We

observed that NS5A significantly promoted G6Pase gene expression (Fig. 7A). Moreover, both the NS5A and NS4A proteins significantly enhanced PEPCK gene expression at 3 and 5 days posttransfection, respectively (Fig. 7B). The expression of each of the HCV proteins except NS2 was verified by immunoblot analysis (Fig. 7C). NS2 was reported previously to be unstable and rapidly degraded by the proteasome (22).

Next, we performed a luciferase reporter assay to examine

the possible effects of NS5A and NS4A on PEPCK promoter activities. The construct rPEPCK-P5(-1263)-pGL3basic carries 1,263 bp of the PEPCK 5'-flanking region (-1263 PEPCK) and is used to monitor PEPCK promoter activity. The results demonstrated that the levels of PEPCK promoter activities were significantly higher in both NS5A- and NS4A-expressing cells than in the control cells (Fig. 7D). Interestingly, when the region of the PEPCK promoter from positions -1263 to -998 was deleted, the activation of PEPCK promoter activity in cells expressing NS5A and NS4A was abolished. These results confirmed that NS5A and NS4A activate the PEPCK promoter, leading to an increase in PEPCK mRNA expression levels. Database searches of the deleted sequence did not reveal any potential binding sequences for transcription factors (data not shown).

Recently reported data suggest that ROS production is induced in NS5A-expressing cells (17) or in hepatocytes of NS5A transgenic mice (68). We therefore sought to determine whether NS5A contributes to increased hepatic gluconeogenesis through the induction of ROS production. The NS5A expression plasmid was transfected into Huh-7.5 cells, and ROS production was assessed by MitoSOX at 3 days posttransfection. As shown in Fig. 8A and B, approximately 30% of NS5A-expressing cells displayed a much stronger signal than that observed for vector-transfected control cells.

We then examined whether NS5A mediated JNK/c-Jun activation and FoxO1 phosphorylation inhibition. The results obtained revealed that both the phosphorylation level at Ser63 and the total expression level of c-Jun were upregulated in NS5A-expressing cells compared to the control cells transfected with the vector plasmid or cells expressing the other HCV proteins (Fig. 8C and D, top two panels). Concomitantly, FoxO1 phosphorylation at Ser319 was clearly suppressed in NS5A- and NS4A-expressing cells compared to the control cells (Fig. 8C, compare lanes 6, 5, and 1, respectively, in the third panel). NS4A, a small protein of ca. 7 kDa, forms a stable complex with NS3 to function as a cofactor for NS3 serine protease and RNA helicase activities (51). We previously reported that NS4A caused mitochondrial damage when expressed alone but not when coexpressed with NS3 (47). We therefore speculated that the otherwise observed decrease in FoxO1 phosphorylation levels in NS4A-expressing cells might be canceled when NS4A is coexpressed with NS3. To verify this notion, we tested FoxO1 phosphorylation in cells coexpressing NS3 and NS4A. As had been expected, FoxO1 phosphorylation levels did not differ between NS3/4A-coexpressing cells and vector-transfected control cells (Fig. 8C, compare lanes 4 and 1, respectively).

Notably, we observed that the HCV core protein did not alter the phosphorylation status of c-Jun and FoxO1 (Fig. 8C, compare lanes 1 and 2), with the result being consistent with what was observed for gene expression levels of PEPCK and G6Pase in HCV core-expressing cells (Fig. 7A and B). These results imply that core is not primarily involved in HCV-induced increased gluconeogenesis under our experimental conditions. Similarly, other HCV nonstructural proteins, such as NS4B and NS5B, did not significantly influence the phosphorylation status of c-Jun and FoxO1 (Fig. 8D).

In order to further verify the effect of NS5A on the nuclear accumulation of FoxO1, we examined the subcellular localiza-

tion of FoxO1 in NS5A-expressing cells by indirect immunofluorescence staining. As shown in Fig. 8E and F, the nuclear accumulation of FoxO1 was clearly observed for approximately 25% of NS5A-expressing cells but not the vector-transfected control. These results suggest that NS5A activates the JNK/c-Jun signaling pathway via increased ROS production, which results in the decreased phosphorylation and nuclear accumulation of FoxO1.

Finally, we examined the effects of NS5A and NS4A on glucose production. As shown in Fig. 9, the amounts of glucose were significantly increased in culture supernatants of NS5A- and NS4A-expressing cells, compared with the amounts of glucose in control cells, at 5 days posttransfection. Again, it is reasonable to assume that the observed increase in glucose production in NS4A-expressing cells might be canceled when NS4A is coexpressed with NS3.

These results collectively suggest that NS5A plays a role, at least to some extent, in the HCV-induced enhancement of hepatic gluconeogenesis.

DISCUSSION

Hepatocytes play an important role in maintaining plasma glucose homeostasis by adjusting the balance between hepatic glucose production and utilization via the gluconeogenic and glycolytic pathways, respectively. We previously reported that HCV suppresses cellular glucose uptake by downregulating the surface expression of the glucose transporters GLUT1 and GLUT2 (37). In this study, we have demonstrated that HCV promotes FoxO1-mediated hepatic gluconeogenesis, as evidenced by the increased accumulation of FoxO1 in the nucleus via the reduction of its phosphorylation status (Fig. 3 and 6A and B), which leads to increased PEPCK and G6Pase gene expression levels (Fig. 1A and B) and the subsequent upregulation of G6P and glucose production (Fig. 2). Moreover, our results indicate that HCV-induced ROS production causes JNK activation, which results in the decreased phosphorylation and nuclear accumulation of FoxO1, leading eventually to increased glucose production (Fig. 4 to 6). Our results thus suggest that FoxO1 is a prime transcription factor in the HCV-mediated progression of hepatic gluconeogenesis through an ROS/JNK-dependent mechanism, as summarized in the schema in Fig. 10. Our results also suggest that HCV NS5A plays a role in enhanced hepatic gluconeogenesis by promoting ROS production and JNK activation (Fig. 7 to 9). In line with our observations, the NS5A-mediated induction of ROS production (68) and JNK activation (49) was reported previously by other investigators.

Increasing evidence suggests that mitochondrial dysfunction is causative of insulin resistance and type 2 diabetes. Mitochondrial dysfunction causes the upregulation of PEPCK and G6Pase, leading to increased gluconeogenesis and insulin resistance (42, 46). We previously reported that HCV causes mitochondrial damage and mitochondrion-mediated apoptosis (14, 47). Our current data further support the concept that altered mitochondrial function plays a role in the development of increased glucose production in hepatocytes.

We and other groups have reported that HCV infection increases the production of mitochondrial ROS, which plays an important role in the development and progression of inflam-




FIG. 8. HCV NS5A is involved in increased ROS production, JNK activation, FoxO1 phosphorylation suppression, and FoxO1 nuclear accumulation. (A) NS5A promotes ROS production. Huh-7.5 cells transfected with an NS5A expression plasmid or the empty control (vector) were incubated with MitoSOX (top) at 3 days posttransfection and then stained for NS5A by using anti-NS5A mouse monoclonal antibody, followed by FITC-conjugated goat anti-mouse IgG (bottom). (B) Quantification of MitoSOX-stained cells. The percentages of cells stained with MitoSOX were determined for NS5A-expressing cells and control cells. Data represent means \pm SEM of data from two independent experiments. *, $P < 0.01$. (C and D) HCV NS5A activates c-Jun phosphorylation and suppresses FoxO1 phosphorylation. Huh-7.5 cells transfected with the indicated HCV viral protein expression plasmids were harvested at 3 days posttransfection, and the whole-cell lysates were subjected to immunoblot analysis using antibodies against phospho-c-Jun (Ser63), c-Jun, phospho-FoxO1 (Ser319), FoxO1, GAPDH, core, NS3, NS4A, and NS5A (C) or c-Myc (D). The amounts of GAPDH were measured as an internal control to verify equal amounts of sample loading. (E) NS5A facilitates FoxO1 nuclear accumulation. Huh-7.5 cells transfected with an NS5A expression plasmid or the empty control (vector) were fixed and permeabilized at 3 days posttransfection. The cells were incubated with an anti-FoxO1 rabbit monoclonal antibody followed by Alexa Fluor 488-conjugated goat anti-rabbit IgG (top) or with anti-NS5A mouse monoclonal antibody followed by Alexa Fluor 594-conjugated goat anti-mouse IgG (bottom). (F) The percentages of cells with a nuclear localization of FoxO1 were determined for NS5A-expressing cells and control cells. Data represent means \pm SEM of data from two independent experiments. *, $P < 0.01$.




FIG. 9. HCV NS5A and NS4A enhance glucose production. (A) Huh-7.5 cells were transfected with either an NS5A or NS4A expression plasmid. At 5 days posttransfection, extracellular glucose production was measured and normalized to the total cellular protein expression level. Data represent means \pm SEM of data from two independent experiments, and the values for the control cells were arbitrarily expressed as 1.0. *, $P < 0.05$ compared with the control. (B) Cellular expression levels of NS4A and NS5A in the absence and presence of sodium lactate (SL) and sodium pyruvate (SP) are shown.

matory liver disease mediated by HCV (12, 14). Increased mitochondrial ROS generation was also shown previously to be an underlying mediator of multiple forms of insulin resistance, including inflammation- or glucocorticoid-induced insulin resistance (27, 29). Moreover, a significant correlation was observed between oxidative stress and insulin resistance in patients infected with HCV genotype 1 or 2 (44). ROS have also been shown to regulate the activity of the FoxO transcription factor by posttranslational modifications, including phosphorylation (21), deacetylation (8), and ubiquitylation (67).

Although this study showed that JNK induces the nuclear accumulation of FoxO1 by reducing its phosphorylation status under oxidative stress conditions in HCV-infected cells, the precise mechanism(s) of the interplay between JNK and FoxO1 still remains to be addressed. It was reported previously that activated JNK phosphorylates IRS-1 at Ser307, which results in attenuated insulin signal transduction through the inhibition of the tyrosine phosphorylation of IRS-1 (1). Akt is a major downstream signaling protein for insulin/IRS-1 signaling and is activated through its phosphorylation on Thr308 and Ser473, the latter of which is believed to be more crucial (53). Therefore, an impairment of the insulin/IRS-1 signaling pathway should involve the downregulation of Akt phosphorylation. However, our present data showed that Akt phosphorylation on Ser473 was upregulated in HCV-infected cells at 4 and 6 dpi (Fig. 3B), suggesting that an Akt-independent pathway is involved in the JNK-mediated suppression of FoxO1 phosphorylation. Regarding this connection, it should be noted that the 14-3-3 protein, a binding partner for phosphorylated FoxO1 that mediates its nuclear export (72), is phosphorylated by JNK and that the phosphorylated 14-3-3 protein releases its




FIG. 10. Schematic representation of the HCV-dysregulated hepatic gluconeogenesis signaling pathway. HCV induces mitochondrial dysfunction (14). This results in increased ROS production and JNK activation, which induces the nuclear accumulation of FoxO1 by reducing its phosphorylation status. Consequently, PEPCK and G6Pase gene expressions are upregulated, leading to an upregulation of G6P and glucose production. NS5A plays a role in HCV-induced gluconeogenesis via the induction of ROS production. IRE, insulin response element.

binding partners, which would facilitate the nuclear accumulation of FoxO (63, 65, 70). Further studies are needed to elucidate this issue.

Another trigger that causes excessive JNK activation and insulin resistance is endoplasmic reticulum (ER) stress (28, 48). Several previous studies reported that HCV infection induces ER stress (34, 55). Under our experimental conditions, however, we did not detect significant ER stress in HCV-infected cells (14). It is thus likely that ER stress was not the primary cause of the increased gluconeogenesis in our experimental system using Huh-7.5 cells and the P-47 strain of HCV J6/JFH-1 (9, 14).

Notably, our present data showed that cells harboring the SGR or FGR and HCV-infected cells produced greater amounts of glucose than did the control cells (Fig. 2A); however, the changes in the phosphorylation status of FoxO1 and JNK in SGR- and FGR-harboring cells were not so significant compared to those in virus-infected cells (data not shown). One of the reasons for this difference is that SGR- and FGR-harboring cells were obtained through a longer cultivation in a selection medium for a month or more and that the balance of host gene induction may be somewhat different from that in virus-infected cells. Therefore, it is possible that, in addition to the JNK-FoxO1 pathway, another signaling pathway(s) is involved in the increased gluconeogenesis in SGR- and FGR-harboring cells. Studies on this issue are now under way in our laboratory.

We observed that HCV infection modulated, either positively or negatively, the transcription of the PEPCK, G6Pase, and GK genes at 3 to 5 dpi (Fig. 1). Virus infection, in general, causes dynamically changing induction and the suppression of a wide variety of host genes. For example, expression levels of certain genes, such as interferon genes, increase during an